DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-15 22:01 |
Monthly information regarding the total number of voting rights and total numbe…
|
English | 160.1 KB | ||
| 2020-07-10 15:00 |
DBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension…
|
English | 261.7 KB | ||
| 2020-07-10 15:00 |
DBV Technologies annonce la publication dans le Journal of Allergy and Clinical…
|
French | 253.2 KB | ||
| 2020-06-26 08:30 |
DBV Technologies fait le point sur ses opérations et sur son activité
|
French | 227.7 KB | ||
| 2020-06-26 08:30 |
DBV Technologies Provides Operational and Business Update
|
English | 223.3 KB | ||
| 2020-03-30 22:00 |
Modalités de mise à disposition des documents préparatoires à l'assemblée génér…
|
French | 217.9 KB | ||
| 2020-03-04 22:30 |
DBV Technologies présente ses résultats financiers pour l’exercice 2019 et fait…
|
French | 269.0 KB | ||
| 2020-03-04 22:30 |
DBV Technologies Reports Full-Year 2019 Financial Results and Provides Business…
|
English | 210.9 KB | ||
| 2020-03-04 22:01 |
DBV Technologies annonce le règlement-livraison des actions ordinaires suppléme…
|
French | 234.7 KB | ||
| 2020-03-04 22:01 |
DBV Technologies Announces Closing of Underwriters’ Option to Purchase Addition…
|
English | 193.3 KB | ||
| 2020-03-02 07:30 |
DBV Technologies annonce l’exercice partiel de l’option de surallocation consen…
|
French | 220.1 KB | ||
| 2020-03-02 07:30 |
DBV Technologies Announces Partial Exercise of Underwriters’ Option to Purchase…
|
English | 211.6 KB | ||
| 2020-02-24 22:00 |
DBV Technologies to Present Detailed Safety and Efficacy Data of Viaskin Peanut…
|
English | 220.4 KB | ||
| 2020-02-24 22:00 |
DBV Technologies présentera des données détaillées sur la sécurité et l’efficac…
|
French | 182.3 KB | ||
| 2020-02-21 15:29 |
DBV Technologies annonce la tenue de la réunion du Comité Consultatif de la FDA…
|
French | 179.0 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
